This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Martha Q. Lacy, MD; William J. Hogan, MRCPI; Morie A. Gertz, MD; Angela Dispenzieri, MD; S. Vincent Rajkumar, MD; Suzanne Hayman, MD; Shaji Kumar, MD; Mark R. Litzow, MD; Arnold L. Schroeter, MD

Arch Dermatol. 2005;141:1277-1282.

Background  Scleromyxedema is a rare chronic fibromucinous disorder that can have devastating clinical manifestations, including sclerosis of the skin with progressive pharyngeal and upper airway involvement, resulting in high mortality due to respiratory complications. Herein we describe a novel therapeutic approach. Because autologous hematopoietic stem cell transplantation is effective in other plasma cell proliferative disorders, it may be effective in this setting.

Observations  We retrospectively evaluated 6 patients who were offered high-dose chemotherapy with stem cell rescue as treatment for scleromyxedema. One heavily pretreated patient was unable to mobilize stem cells. The remaining 5 patients mobilized stem cells and underwent successful transplantation. There was no treatment-related mortality. Hematologic responses were seen in 4 patients, including 2 complete remissions and 2 partial remissions, and all 4 had improvement in extracutaneous manifestations. All 4 patients subsequently had relapse of the monoclonal protein, and 3 developed skin relapses at 14, 37, and 45 months.

Conclusions  High-dose chemotherapy with stem cell rescue is feasible for patients with scleromyxedema and, although not curative, offers durable remission in most patients. This therapy should be considered before treatment with alkylating agents or other treatments that could adversely affect the ability to collect stem cells.

Author Affiliations: Division of Hematology and Internal Medicine, Department of Internal Medicine (Drs Lacy, Hogan, Gertz, Dispenzieri, Rajkumar, Hayman, Kumar, and Litzow) and Department of Dermatology (Dr Schroeter), Mayo Clinic and Mayo Foundation, Rochester, Minn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study.
Illa et al.
Blood 2006;108:773-774.
FULL TEXT  

Autologous Peripheral Stem-Cell Transplantation a Temporary Success for Scleromyxedema
Journal Watch Dermatology 2005;2005:5-5.
FULL TEXT